Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
1. CRL reported Q4 2024 revenue at $1 billion, beating estimates. 2. Operating margin fell to (16.7)%, impacted by a $215 million impairment. 3. Adjusted EPS rose to $2.66, surpassing consensus of $2.53. 4. 2025 revenue guidance suggests decline of 7% to 4.5%. 5. Analysts remain cautious, maintaining Market Perform rating for CRL.